Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

P 22077

Catalog No: tcsc1860

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1247819-59-5

Formula:
$C_{12}H_7F_2NO_3S_2$

Pathway:
Cell Cycle/DNA Damage

Target:
Deubiquitinase

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 53.3 mg/mL (169.03 mM)

Observed Molecular Weight:
315.32

Product Description

P 22077 is a cell-permeable **ubiquitin-specific protease 7 (USP7)** inhibitor with an **EC_{50}** of 8.01 μM. It also inhibits USP47 with an **EC_{50}** of 8.74 μM.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 & Target: EC50: 8.01 μM (USP7), 8.74 μM (USP47)[1]

In Vitro: P 22077 is an inhibitor of USP7 and DUB USP47, with EC_{50}s of 8.01 μM and 8.74 μM, respectively. P 22077 (15-45 μM) inhibits a much smaller subset of DUBs. P 22077 (25 μM) causes DUBs inhibition in HEK293T cells[1]. P 22077 (0-20 μM) greatly reduces the cell viability of Neuroblastoma (NB) cells including IMR-32, NGP, CHLA-255, and SH-SY5Y cells but without NB-19 and SK-N-AS cells. P 22077 (10 μM) increases p53 activity and induces apoptosis in p53 wild-type and HDM2-expressing NB cells. P 22077 (5 μM) enhances the cytotoxic effect of Dox and VP-16 on NB cells, and enhances Dox- and VP-16-induced p53-mediated apoptosis[2].

In Vivo: P 22077 (15 mg/kg, i.p. 21 days) shows potent antitumor activities in an xenograft mouse model bearing IMR-32-derived tumors; P 22077 also exhibits antitumor effects after treatment at 10 mg/kg for 14 days in mice bearing SH-SY5Y-derived tumors, and at 20 mg/kg for 12 days in mice bearing NGP-derived tumors[2].